STOCK TITAN

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Positive
  • None.
Negative
  • None.

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com


FAQ

When will CRISPR Therapeutics present at the 42nd Annual J.P. Morgan Healthcare Conference?

CRISPR Therapeutics will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 2:15 p.m. PT in San Francisco.

Where can I watch the live webcast of CRISPR Therapeutics' presentation?

The live webcast of CRISPR Therapeutics' presentation will be available on the 'Events & Presentations' page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.

How long will the replay of CRISPR Therapeutics' webcast be available?

The replay of CRISPR Therapeutics' webcast will be archived on the Company's website for 14 days following the presentation.

CRISPR Therapeutics AG

NASDAQ:CRSP

CRSP Rankings

CRSP Latest News

CRSP Stock Data

4.57B
78.84M
1.35%
65.69%
18.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ZUG

About CRSP

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.